Perspectives of Ketamine Use in COVID-19 Patients

Hospitalized coronavirus disease 2019 (COVID-19)-infected patients suffer from both physical impairments and mental stress. Respiratory insufficiency and cardiovascular disturbances require most of the intensive care interventions, but they are also accompanied by depressive conditions, sadness and...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Korean medical science 2021, 36(4), , pp.1-5
Main Author: Weinbroum, Avi A
Format: Article
Language:English
Subjects:
Anesthesia
Anxiety - drug therapy
Brief Communication
COVID-19 - drug therapy
COVID-19 - psychology
Critical Care
Depression - complications
Depression - drug therapy
Hemodynamics
Hospitalization
Humans
Hypnotics and Sedatives
Immune System
Ketamine - therapeutic use
Respiratory Insufficiency
Stress, Psychological - complications
Stress, Psychological - drug therapy
Suicidal Ideation
Treatment Outcome
의학일반
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hospitalized coronavirus disease 2019 (COVID-19)-infected patients suffer from both physical impairments and mental stress. Respiratory insufficiency and cardiovascular disturbances require most of the intensive care interventions, but they are also accompanied by depressive conditions, sadness and fear of dying. Sedatives are mostly respiratory and cardiovascular depressants and do not provide resistance to the pro-inflammatory burst induced by the virus. Ketamine is a unique and safe drug that enables well-controlled sedation and anesthesia, attenuates depression and mitigates suicidal thoughts, without depressing respiratory or cardiovascular mechanics. This brief communication highlights the benefits potentially provided by ketamine to patients hospitalized for COVID-19 infection.
ISSN:1011-8934
1598-6357
DOI:10.3346/jkms.2021.36.e28